Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo …
WEB7 hours ago · On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...
In sustained rare disease push, Recordati lays out $825M upfront …
WEB8 hours ago · Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo.
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for …
WEB22 hours ago · Enjaymo generated €72 million (about $79 million) in sales last year, a 240% increase over the product’s sales in 2022, according to Sanofi’s annual report. Sales for Enjaymo are continuing ...
Sanofi’s rare disease drug finds yet another home
WEB7 hours ago · From the Bioverativ acquisition, Sanofi got Enjaymo as well as another now-marketed hemophilia medicine, Altuviiio. According to Recordati, Enjaymo generated around 100 million euros, or roughly $108 million, over the 12-month period between September 2023 and August 2024.
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
WEB22 hours ago · Enjaymo’s targeted mechanism of action inhibits the C1s in the classical complement pathway, preventing the abnormal breakdown of red blood cells. The approval of Enjaymo by the FDA in February 2022 marked a significant milestone as the first and only treatment aimed at reducing the need for red blood cell transfusions in …
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB16 hours ago · Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
WEB15 hours ago · Global News Select Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million Provided by ... Enjaymo's revenue amounted to around 100 million euros ($110.3 million) for the 12 months to ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB22 hours ago · Recordati will host a conference call today, 4 th October, at 13:00 CEST (12:00 p.m. GMT) to discuss the agreement to acquire Enjaymo®.The dial-in numbers for the conference call service are ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB16 hours ago · Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults ...
FDA Approves Enjaymo® after pivotal study results | Sanofi
WEBFeb 4, 2022 · FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease. Enjaymo is the only approved treatment to decrease the need for red blood cell transfusion due to hemolysis, the destruction of red blood cells, in adults with cold agglutinin disease (CAD)
- Some results have been removed